

06-02-00

Patent Application Transmittal
(only for new nonprovisional applications
under 37 C.F.R. 1.53(b))
Correspondence Address:
FROMMER LAWRENCE & HAUG LLP
745 Fifth Avenue
New York, New York 10151
Tel. (212) 588-0800 Fax: (212) 588-0500

Re: 454313-2335.1

TO: ASSISTANT COMMISSIONER FOR PATENTS
Box PATENT APPLICATION, Washington, D.C. 20231

Sir:

With reference to the filing in the United States Patent and Trademark Office of an application for patent in the name of:

AUDONNET ET AL.

(information on attached UNSIGNED Declaration & Power of Attorney)

entitled: DNA VACCINE - PCV

☐ This is an application of a small entity under 37 CFR 1.9(f).

☐ Small Entity Verified Statement is enclosed (unsigned)

The following are enclosed:

☒ Specification (29 pages, plus 1 page of abstract on page 32.)

☒ (5) Sheet(s) of Drawings (FIGURES 1-5)

☒ 11 Claims (pp. 30-31)

☒ SEQUENCE LISTING (4 pages)

☒ Oath or Declaration and Power of Attorney (unsigned)

☒ The filing fee will be paid and an executed Declaration and Power of Attorney will be filed upon receipt of a Notice To File Missing Parts. Kindly accord the application a MAY 31, 2000 filing date.

Respectfully submitted,
FROMMER LAWRENCE & HAUG LLP
Attorneys for Applicants

By: Thomas J. Kowalski
Thomas J. Kowalski, Reg. No. 32,147

EXPRESS MAIL

Mailing Label Number EL560677945US

Date of Deposit. May 31, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Edward Nay
(Typed or printed name of person mailing paper or fee)

Edward Nay
(Signature of person mailing paper or fee)

SJL2755

DNA Vaccine - PCV

RELATED APPLICATIONS:

Reference is made to US Applications Serial Nos. 60/138,352, filed June 10, 1999, 09/082,558, filed 21 May 1998 and to US
5 Application Serial No. 09/161,092 filed on 25 September 1998 in the form of a continuation-in-part of application Serial 09/082,558; these applications being incorporated herein by way of reference, and each document cited in the present application also incorporated herein by way of reference.
10 (Reference is made to U.S. applications Serial Nos. 60/138,352, filed June 10, 1999, 09/161,092, filed 09/25/98 as a CIP of U.S. application Serial No. 09/082,558, filed 05/21/98, claiming priority from French Application Nos.97/12382, 98/00873, 98/03707, filed 10/03/97, 1/22/98,
15 3/20/98; each of which, and each document cited therein, incorporated herein by reference). This application is based on and claims priority from U.S. application Serial No. 60/138,352, filed June 10, 1999.

The present invention relates to plasmid
20 constructs encoding and expressing porcine circovirus (PCV for Porcine CircoVirus) immunogens responsible for the PMWS syndrome (Porcine Multisystemic Wasting Syndrome or Post-Weaning Multisystemic Wasting Syndrome), to methods of vaccination and to DNA
25 vaccines, as well as to methods of producing and of formulating these vaccines. All documents cited herein, and all documents cited in documents cited herein are hereby incorporated herein by reference.

PCV was originally detected as a
30 noncytopathogenic contaminant in pig kidney cell lines PK/15. This virus was classified among the *Circoviridae* with the chicken anaemia virus (CAV for Chicken Anaemia Virus) and the PBFDV virus (Pscittacine Beak and Feather Disease Virus). These are small nonenveloped
35 viruses (from 15 to 24 nm) whose common characteristic is to contain a genome in the form of a circular single-stranded DNA of 1.76 to 2.31 kilobases (kb). It was first thought that this genome encoded a polypeptide of about 30 kDa (Todd *et al.*, Arch. Virol.,
40 1991, 117: 129-135). Recent work has however shown a

more complex transcription (Meehan B.M. et al., J. Gen. Virol., 1997, **78**: 221-227). Moreover, no significant homologies in nucleotide sequence or in common antigenic determinants are known between the three species of circoviruses known.

The PCV derived from PK/15 cells is considered not to be pathogenic. Its sequence is known from B.M. Meehan et al., J. Gen. Virol. 1997 (**78**) 221-227. It is only very recently that some authors have thought that strains of PCV could be pathogenic and associated with the PMWS syndrome (G.P.S. Nayar et al., Can. Vet. J., 1997, **38**: 385-387 and Clark E.G., Proc. Am. Assoc. Swine Prac. 1997: 499-501). Nayar et al. have detected PCV DNA in pigs having the PMWS syndrome using PCR techniques.

Monoclonal and polyclonal antibodies directed against circoviruses found in pigs having the symptoms of the PMWS syndrome have been able to demonstrate differences between these circoviruses and the porcine circoviruses isolated from culture of PK-15 cells (Allan G.M. et al. Vet Microbiol., 1999, **66**: 115-123).

The PMWS syndrome detected in Canada, the United States and France is clinically characterized by a gradual loss of weight and by manifestations such as tachypnea, dyspnea and jaundice. From the pathological point of view, it is manifested by lymphocytic or granulomatous infiltrations, lymphadenopathies and, more rarely, by hepatitis and lymphocytic or granulomatous nephritis (Clark E. G., Proc. Am. Assoc. Swine Prac. 1997: 499-501; La Semaine Vétérinaire No. 26, supplement to La Semaine Vétérinaire 1996 (834); La Semaine Vétérinaire 1997 (857): 54; G.P.S. Nayar et al., Can. Vet. J., 1997, **38**: 385-387).

These circoviruses obtained from North America and from Europe are very closely related, with a degree of identity of more than 96% of their nucleotide sequence, whereas the degree of identity is less than 80% when the nucleotide sequences of these circoviruses are compared with those of porcine circoviruses

isolated from PK-15 cells. Accordingly, two viral subgroups have been proposed, PCV-2 for the circoviruses associated with the PMWS syndrome and PCV-1 for the circoviruses isolated from the PK-15 cells (Meehan B.M. et al., J. Gen. Virol., 1998, **79**: 2171-2179; WO-A-9918214).

The Applicant has found that plasmid constructs encoding and expressing PCV-2 immunogens can be used to immunize pigs against the PMWS syndrome.

PCV-2 immunogens can be used in combination with PCV-1 immunogens to also immunize these animals against PCV-2.

According to a less preferred mode, the PCV-1 immunogens may be used alone.

The subject of the present invention is plasmid constructs encoding and expressing a PCV-1 or PCV-2 immunogen, in particular the open reading frames (ORFs) 1 and/or 2 for PCV-1, and the ORFs 1 and/or 2 for PVC-2 (ORF means Open Reading Frame).

It goes without saying that the invention automatically covers the plasmids encoding and expressing equivalent nucleotide sequences, that is to say the sequences which change neither the functionality or the strain specificity (say strain of type 1 and strain of type 2) of the gene considered or those of the polypeptides encoded by this gene. The sequences differing through the degeneracy of the code will, of course, be included.

The PCV-2 sequences used in the examples are derived from Meehan et al. *supra* (Strain Imp.1010 ; ORF1 nucleotides 398-1342; ORF2 nucleotides 1381-314; and correspond respectively to ORF4 and ORF13 in US 09/161,092 of 25 September 1998 and to COL4 and COL13 in WO-A-9918214). Other PCV-2 strains and their sequences have been published in WO-A-9918214 and called Imp1008, Imp999, Imp1011-48285 and Imp1011-48121, as well as in A.L. Hamel et al. J. Virol. June 1998, vol **72**, 6: 5262-5267 (GenBank AF027217) and in I. Morozov et al. J. Clinical Microb.

Sept. 1998 vol. **36**, 9: 2535-2541, as well as GenBank AF086834, AF086835 and AF086836, and give access to equivalent ORF sequences.

5 The invention also covers the equivalent sequences in the sense that they are capable of hybridizing to the nucleotide sequence of the gene considered under high stringency conditions. Among the equivalent sequences, there may also be mentioned the gene fragments conserving the immunogenicity of the
10 complete sequence.

The homology of the whole genome of types 1 and 2 therebetween is about 75%. For ORF1, it is about 86%, and for ORF2, about 66%. On the contrary, homologies between genomes and between ORFs inside type 2 are
15 generally above 95%.

Are also equivalent sequences according to the present invention, for ORF1, those sequences having an homology equal or greater than 88%, in particular than 90%, preferably than 92% or 95% with ORF1 of strain
20 Imp1010, and for ORF2, those sequences having an homology equal or greater than 80%, in particular than 85%, preferably than 90% or 95% with ORF2 of strain Imp1010.

ORF1 and ORF2 according to Meehan 1998 has the
25 potential to encode proteins with predicted molecular weights of 37.7 kD and 27.8 kD respectively. ORF3 and ORF4 (according to Meehan et al. 1998, correspond to ORF7 and ORF10 respectively in WO-A-9918214) has the potential to encode proteins with predicted molecular
30 weights of 11.9 and 6.5 kD respectively. The sequence of these ORFs is also available in Genbank AF 055392. They can also be incorporated in plasmids and be used in accordance with the invention alone or in combination, e.g. with ORF1 and/or ORF2.

35 The other ORFs 1-3 and 5, 6, 8-9, 11-12 disclosed in US 09/161,092 of 25 September 1998 (COLs 1-3 and 5, 6, 8-9, 11-12 in WO-A-9918214), may be used under the conditions described here, in combination or

otherwise with each other or with the ORFs 1 and 2 as defined here.

This also encompasses the use of equivalent sequences in the leaning given above, in particular
5 those ORFs coming from various PCV-2 strains cited herein. For homology, one can precise that are equivalent those sequences which come from a PCV strain having an ORF2 and/or an ORF1 which have an homology as defined above with the corresponding ORF of strain
10 1010. For ORF3 according to Meehan, it can also be said that homology has to be for instance equal or greater than 80%, in particular than 85%, preferably than 90% or 95% with ORF3 of strain Imp1010. For ORF4 according to Meehan 1998, it can be equal or greater than 86%, in
15 particular than 90%, preferably than 95% with ORF4 of strain Imp1010.

From the genomic nucleotide sequence, e.g. those disclosed in WO-A-99 18214, it is routine art to determine the ORFs using a standard software, such as
20 MacVector®. Also, alignment of genomes with that of strain 1010 and comparison with strain 1010 ORFs allows the one skilled in the art to readily determine the ORFs on the genome for another strain (e.g. those disclosed in WO-A-99 18214). Using a software or making
25 alignment is not undue experimentation and give directly access to equivalent ORFs.

The word plasmid is here intended to cover any DNA transcription unit in the form of a polynucleotide sequence comprising the PCV sequence to be expressed
30 and the elements necessary for its expression *in vivo*. The circular plasmid form, supercoiled or otherwise, is preferred. The linear form is also included within the scope of the invention.

The subject of the present invention is more
35 particularly the plasmids called pJP109 (containing the ORF2 gene of PCV-2, Figure 1), pJP111 (containing the ORF1 gene of PCV-2, Figure 2), pJP120 (containing the ORF2 gene of PCV-1, Figure 3) and pJP121 (containing the ORF1 gene of PCV-1, Figure 4).

Each plasmid comprises a promoter capable of ensuring, in the host cells, the expression of the inserted gene under its control. It is in general a strong eukaryotic promoter and in particular a cytomegalovirus early promoter CMV-IE, of human or murine origin, or optionally of other origin such as rat or guinea pig. More generally, the promoter is either of viral origin or of cellular origin. As a viral promoter other than CMV-IE, there may be mentioned the SV40 virus early or late promoter or the Rous Sarcoma virus LTR promoter. It may also be a promoter from the virus from which the gene is derived, for example the promoter specific to the gene. As cellular promoter, there may be mentioned the promoter of a cytoskeleton gene, such as for example the desmin promoter, or alternatively the actin promoter. When several genes are present in the same plasmid, they may be provided in the same transcription unit or in two different units.


The plasmids may also comprise other transcription regulating elements such as, for example, stabilizing sequences of the intron type, preferably intron II of the rabbit β -globin gene (van Ooyen et al. Science, 1979, **206**: 337-344), signal sequence of the protein encoded by the tissue plasminogen activator gene (tPA; Montgomery et al. Cell. Mol. Biol. 1997, **43**: 285-292), and the polyadenylation signal (polyA), in particular of the bovine growth hormone (bGH) gene (US-A-5,122,458) or of the rabbit β -globin gene.

The subject of the present invention is also immunogenic preparations and DNA vaccines comprising at least one plasmid according to the invention, encoding and expressing one of the PCV-1 or PCV-2 immunogens, preferably one of the abovementioned ORFs, in addition a veterinarily acceptable vehicle or diluent, with optionally, in addition, a veterinarily acceptable adjuvant.

The subject of the present invention is more particularly immunogenic preparations and vaccines

containing at least one plasmid encoding and expressing one of the PCV-1 or PCV-2 immunogens, compositions formulated with an adjuvant, in particular a cationic lipid containing a quaternary ammonium salt of formula

5



in which R₁ is a saturated or unsaturated linear aliphatic radical having from 12 to 18 carbon atoms, R₂ is another aliphatic radical comprising from 2 to 3 carbon atoms, and X is an hydroxyle ou amine group.

Preferably it is DMRIE (N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propanammonium; WO-A-9634109), and preferably coupled with a neutral lipid, e.g. preferably DOPE (dioleoylphosphatidylethanolamine), to form DMRIE-DOPE. Preferably, the plasmid mixture with this adjuvant is made immediately before use and preferably, before its administration to the animal, the mixture thus produced is allowed to form a complex, for example over a period ranging from 10 to 60 minutes, in particular of the order of 30 minutes.


When DOPE is present, the DMRIE:DOPE molar ratio preferably ranges from 95:5 to 5:95, more particularly 1:1.

The plasmid:DMRIE or DMRIE-DOPE adjuvant weight ratio may range in particular from 50:1 to 1:10, in particular from 10:1 to 1:5, preferably from 1:1 to 1:2.

According to another advantageous mode of the invention, it is possible to use, as adjuvant, an adjuvant compound selected from the polymers of acrylic or methacrylic acid and the copolymers of maleic anhydride and of alkenyl derivative. The polymers of acrylic or methacrylic acid crosslinked in particular

with polyalkenyl ethers of sugars or of polyalcohols are preferred. These compounds are known by the term carbomer (Pharmeuropa vol. 8, No. 2, June 1996). Persons skilled in the art can also refer to
5 US-A-2,909,462 (incorporated by reference) describing such acrylic polymers crosslinked with a polyhydroxylated compound having at least 3 hydroxyl groups, preferably not more than 8, the hydrogen atoms of at least three hydroxyls being replaced with
10 unsaturated aliphatic radicals having at least 2 carbon atoms. The preferred radicals are those containing 2 to 4 carbon atoms, e.g. vinyls, allyls and other ethylenically unsaturated groups. The unsaturated radicals may themselves contain other substituents,
15 such as methyl. The products sold under the name Carbopol® (GF Goodrich, Ohio, USA) are particularly appropriate. They are crosslinked with an allyl saccharose or with allylpentaerythritol. Among them, there may be mentioned Carbopol® 974P, 934P and 971P.

20 Among the copolymers of maleic anhydride and of an alkenyl derivative, the EMAs® (Monsanto) are preferred which are copolymers of maleic anhydride and ethylene, linear or crosslinked, for example crosslinked with divinyl ether. Reference may be made
25 to J. Fields et al. Nature, 186 : 778-780, 4 June 1960 (incorporated by reference). From the point of view of their structure, the polymers of acrylic or methacrylic acid and the EMAs® preferably consist of basic units of the following formula:



30

in which

- R₁ and R₂, which are identical or different, represent H or CH₃

35 - x = 0 or 1, preferably x = 1

- $y = 1$ or 2 , with $x + y = 2$

For the EMAs®, $x = 0$ and $y = 2$. For the carbomers, $x = y = 1$.

5 The dissolution of these polymers in water leads to an acidic solution which will be neutralized, preferably to physiological pH, to give the adjuvant solution into which the actual vaccine will be incorporated. The carboxyl groups of the polymer are then partly in COO^- form.

10 For this type of adjuvant, it is preferable to prepare a solution of the adjuvant, in particular of carbomer, in distilled water, preferably in the presence of sodium chloride, the solution obtained being at acidic pH. This stock solution is diluted by
15 adding it to the required quantity (in order to obtain the desired final concentration), or a substantial part thereof, of water loaded with NaCl, preferably physiological saline (NaCl 9 g/l), in one or more portions with concomitant or subsequent neutralization
20 (pH 7.3 to 7.4), preferably with NaOH. This solution at physiological pH will be used as it is to mix with the plasmid, in particular stored in lyophilized, liquid or frozen form.

The polymer concentration in the final vaccine
25 composition will be 0.01% to 2% w/v, more particularly 0.06 to 1% w/v, preferably 0.1 to 0.6% w/v.

In a specific embodiment, the immunogenic or vaccine preparation comprises a plasmid or a mixture of plasmids encoding and expressing PCV-2 ORF1 and ORF2.

30 The invention also provides for combining the vaccination against the porcine circovirus with a vaccination against other pig pathogens, in particular those which may be associated with the PMWS syndrome. By way of example, one may cite : Aujeszky's disease
35 virus, porcine influenza virus, PRRS, porcine parvovirus, hog cholera virus, *Actinobacillus pleuropneumoniae*.

The subject of the present invention is thus mixtures of plasmid containing at least one plasmid

according to the invention and at least another plasmid encoding and expressing a porcine immunogen, selected for example from the group consisting of the glycoproteins gB and gD of the Aujeszky's disease virus (pseudorabies virus or PRV), the haemagglutinin and the nucleoprotein of the porcine influenza virus H1N1, the haemagglutinin and the nucleoprotein of the porcine influenza virus H3N2, the ORF5 and ORF3 genes of the PRRS virus of the Lelystad and USA strains, the VP2 protein of the porcine parvovirus, the E1 and E2 proteins of the hog cholera virus (HCV), the deleted apxI, apxII and apxIII genes from *Actinobacillus pleuropneumoniae* (see for the plasmids for example WO-A-9803658).

These mixtures of plasmids are taken up in a veterinarily acceptable vehicle or diluent, with optionally, in addition, a veterinarily acceptable adjuvant as described above, thus forming immunogenic preparations or multivalent DNA vaccines. These preparations or multivalent vaccines may in particular be advantageously formulated with a cationic lipid as described above, in particular DMRIE, and preferably coupled with a neutral lipid, DOPE, to form the DMRIE-DOPE.

The preparations or monovalent or multivalent DNA vaccines according to the invention, formulated or otherwise with an adjuvant as described above, may also be advantageously supplemented with a cytokine preferably of porcine origin, in particular porcine GM-CSF. This addition of porcine GM-CSF (granulocyte macrophage - colony stimulating factor; Clark S.C. et al. Science 1987, **230**: 1229; Grant S.M. et al. Drugs, 1992, **53**: 516) may be carried out in particular by incorporating into the preparation or into the vaccine either porcine GM-CSF protein, or a plasmid encoding and expressing the porcine GM-CSF gene (Inumaru S. and Takamatsu H. Immunol. Cell. Biol., 1995, **73**: 474-476). Preferably, the porcine GM-CSF gene is inserted into a

plasmid different from those encoding the PCV immunogens or the other porcine immunogens.

In particular, the plasmid encoding and expressing the porcine GM-CSF may be the plasmid pJP058
5 (Figure 5).

The immunogenic preparations and the monovalent or multivalent DNA vaccines according to the invention may also be combined with at least one conventional vaccine (attenuated live, inactivated or subunit) or
10 recombinant vaccine (viral vector) directed against at least one porcine pathogen which is different or identical. The invention provides in particular for the combination with adjuvant-containing conventional vaccines (attenuated live, inactivated or subunit). For
15 the inactivated or subunit vaccines, there may be mentioned those containing in particular alumina gel alone or mixed with saponin as adjuvant, or those formulated in the form of an oil-in-water emulsion.

The subject of the present invention is also a
20 method of immunization which makes it possible to induce an immune response in pigs towards the circoviruses according to the invention. Its subject is in particular a method of vaccination which is effective in pigs. These methods of immunization and
25 vaccination comprise the administration of one of the preparations or of one of the monovalent or multivalent DNA vaccines as described above. These methods of immunization and vaccination comprise the administration of one or more successive doses of these
30 preparations or DNA vaccines. The preparations and DNA vaccines may be administered, in the context of this method of immunization or of vaccination, by various routes of administration proposed in the prior art for polynucleotide vaccination, in particular the
35 intramuscular and intradermal routes, and by means of

known administration techniques, in particular injections with a syringe having a needle, by liquid jet (Furth et al. Analytical Bioch., 1992, 205: 365-368) or by projection of gold particles coated with
5 DNA (Tang et al. Nature, 1992, 356: 152-154).

This method not only allows for administration to adult pigs, but also to the young and to gestating females; in the latter case, this makes it possible, in particular, to confer passive immunity onto the
10 newborns (maternal antibodies). Preferably, female pigs are inoculated prior to breeding; and/or prior to serving, and/or during gestation. Advantageously, at least one inoculation is done before serving and it is preferably followed by an inoculation to be performed
15 during gestation, e.g., at about mid-gestation (at about 6-8 weeks of gestation) and/or at the end of gestation (at about 11-13 weeks of gestation). Thus, an advantageous regimen is an inoculation before serving and a booster inoculation during gestation. Thereafter,
20 there can be reinoculation before each serving and/or during gestation at about mid-gestation and/or at the end of gestation. Preferably, reinoculations are during gestation.

Piglets, such as piglets from vaccinated females
25 (e.g., inoculated as herein discussed), are inoculated within the first weeks of life, e.g., inoculation at one and/or two and/or three and/or four and/or five weeks of life. Preferably, piglets are first inoculated within the first week of life or within the third week
30 of life (e.g., at the time of weaning). Advantageously, such piglets are then boosted two to four weeks later.

The quantity of DNA used in the vaccines according to the present invention is between about 10 µg and about 2000 µg, and preferably between about
35 50 µg and about 1000 µg. Persons skilled in the art

will have the competence necessary to precisely define the effective dose of DNA to be used for each immunization or vaccination protocol.

The dose volumes may be between 0.5 and 5 ml, preferably between 2 and 3 ml.

A preferred method of immunization or of vaccination consists in the administration of the DNA vaccines according to the invention by the intramuscular route.

The invention will now be described in greater detail with the aid of nonlimiting exemplary embodiments, taken with reference to the drawing, in which:

- Figure 1: plasmid pJP109
- 15 Figure 2: plasmid pJP111
- Figure 3: plasmid pJP120
- Figure 4: plasmid pJP121
- Figure 5: plasmid pJP058
- 20 Sequence listing SEQ ID
- SEQ ID No. 1: oligonucleotide JP779
- SEQ ID No. 2: oligonucleotide JP780
- SEQ ID No. 3: oligonucleotide JP781
- SEQ ID No. 4: oligonucleotide JP782
- 25 SEQ ID No. 5: oligonucleotide JP783
- SEQ ID No. 6: oligonucleotide JP784
- SEQ ID No. 7: oligonucleotide JP785
- SEQ ID No. 8: oligonucleotide JP786
- SEQ ID No. 9: oligonucleotide RG972
- 30 SEQ ID No. 10: oligonucleotide RG973

EXAMPLES

PCV-2 strains useful for cloning ORFs are for instance strains deposited at the ECACC and having the accession numbers V97100219 (Imp1008), V97100218 (Imp1010) and V97100217 (Imp999) (which were deposited on October 2, 1997), V98011608 (Imp1011-48285) and V98011609

(Imp1011-48121) (which were deposited on January 16, 1998).

These examples are constructed using strain Imp1010. The one skilled in the art is able to adapt the process to other PCV-2 strains.

Example 1 Construction of the plasmid pJP109

The plasmid pGEM7Z-Imp1010 Stoon-EcoRI No. 14 containing the genome of the PCV-2 virus in the form of an EcoRI fragment (B. Meehan et al. J. Gen. Virol. 1998. 79 2171-2179) was digested with EcoRI in order to isolate, after agarose gel electrophoresis, the EcoRI-EcoRI fragment of 1768 base pairs (bp). This fragment was self-ligated.

The ORF2 gene of the PCV-2 virus strain 1010-Stoon (B. Meehan et al. J. Gen. Virol. 1998. 79. 2171-2179; GenBank sequence accession No. AF055392) was amplified, using the template consisting of the self-ligated EcoRI-EcoRI fragment, by the polymerase chain reaction (PCR) technique with the following oligonucleotides:

JP779 (SEQ ID NO 1) (35 mer):

5'CATCATCATGTCGACATGACGTATCCAAGGAGGCG3'

and JP780 (SEQ ID NO 2) (36 mer):

5'TACTACTACAGATCTTTAGGGTTTAAGTGGGGGGTTC3'

in order to generate a 730 bp PCR fragment. This fragment was digested with SalI and BglII in order to isolate, after agarose gel electrophoresis, the 715 bp SalI-BglII restriction fragment. This fragment was then ligated with the plasmid pVR1012 (Hartikka J. et al. Human Gene Therapy. 1996. 7. 1205-1217), digested beforehand with SalI and BglII, to give the plasmid pJP109 (5567 pb) (Figure 1).

Example 2: Construction of the plasmid pJP111

A polymerase chain reaction was carried out with the plasmid pGem7Z-Imp1010-Stoon (see Example 1) (B. Meehan et al. J. Gen. Virol. 1998. 79. 2171-2179), and the following oligonucleotides:

JP781 (SEQ ID NO 3) (35 mer):

5'CATCATCATGTCGACATGCCCAGCAAGAAGAATGG3'

and JP782 (SEQ ID NO 4) (36 mer):

5'TACTACTACAGATCTTCAGTAATTTATTTTCATATGG3'

in order to generate a 970 bp PCR fragment containing
5 the ORF1 gene of the PCV-2 virus. This fragment was
digested with SalI and BglII in order to isolate, after
agarose gel electrophoresis, the 955 bp SalI-BglII
restriction fragment. This fragment was then ligated
with the plasmid pVR1012 (Example 1) to give the
10 plasmid pJP111 (5810 bp) (Figure 2).

**Example 3: Construction of the plasmid pJP120 (PCV-1
ORF2)**

A polymerase chain reaction was carried out with the
15 plasmid pPCV1 (B. Meehan et al. J. Gen. Virol. 1997.
78, 221-227), and the following oligonucleotides;

JP783 (SEQ ID NO 5) (35 mer):

5'CATCATCATGTCGACATGACGTGGCCAAGGAGGCG3'

and JP784 (SEQ ID NO 6) (40 mer):

20 5'TACTACTACAGATCTTTATTTATTTAGAGGGTCTTTTAGG3'

in order to generate a 730 bp PCR fragment containing
the ORF2 gene of the PCV-1 virus (PK-15 strain, GenBank
sequence accession No. U49186). This fragment was
digested with SalI and BglII in order to isolate, after
25 agarose gel electrophoresis, the 715 bp SalI-BglII
restriction fragment. This fragment was then ligated
with the plasmid pVR1012 (Example 1) to give the
plasmid pJP120 (5565 bp) (Figure 3).

30 **Example 4: Construction of the plasmid pJP121 (PCV-1
ORF1)**

The plasmid pPCV1 containing the PCV1 virus genome in
the form of a PstI fragment (B. Meehan et al. J. Gen.
Virol. 1997, 78, 221-227) was digested with PstI in
35 order to isolate, after agarose gel electrophoresis,
the 1759 base pair (bp) PstI-PstI fragment. This
fragment was self-ligated.

The ORF1 gene of the PCV-1 virus strain PK-15
(B. Meehan et al. J. Gen. Virol. 1997, 78, 221-227;

GenBank sequence accession No. U49186) was amplified, using the template consisting of the self-ligated PstI-PstI fragment, by the polymerase chain reaction (PCR) technique with the following oligonucleotides:

5 JP785 (SEQ ID NO 7) (35 mer):

5'CATCATCATGTCGACATGCCAAGCAAGAAAAGCGG3'

and JP786 (SEQ ID NO 8) (36 mer):

5'TACTACTACAGATCTTCAGTAATTTATTTTATATGG3'

in order to generate a 965 bp PCR fragment containing the ORF1 gene of the PCV-1 virus (strain PK-15). This fragment was digested with SalI and BglII in order to isolate, after agarose gel electrophoresis, the 946 bp SalI-BglII restriction fragment. This fragment was then ligated with the plasmid pVR1012 (Example 1) to give the plasmid pJP121 (5804 bp) (Figure 4).

Example 5: Construction of the plasmid pJP058 (expressing porcine GM-CSF)

Pig blood was collected over a tube containing EDTA by taking blood from the jugular vein. The mononucleated cells were harvested by centrifugation on a Ficoll gradient and then cultured *in vitro* in RPMI 1640 medium (Gibco-BRL) and stimulated by addition of concanavaline A (Sigma) at a final concentration of about 5 µg/ml in the culture medium. After 72 hours of stimulation, the lymphoblasts were harvested and the total RNA of these cells was extracted with the extraction kit "Micro-Scale Total RNA Separator Kit" (Clontech) following the manufacturer's recommendations. A reverse transcription reaction, carried out with the aid of the kit "1st-Strand cDNA Synthesis Kit" (Perkin Elmer), followed by a polymerase chain reaction, was carried out on the total RNA extracted from these porcine lymphoblasts with the following oligonucleotides:

35

RG972 (33 mer): (SEQ ID No. 9)

5'TATGCGGCCGCCACCATGTGGCTGCAGAACCTG3'

and RG973 (34 mer): (SEQ ID No. 10)

5'TATGCGGCCGCTACGTATCACTTCTGGGCTGGTT3'

in order to generate a PCR fragment of about 450 base pairs (bp). This fragment was digested with NotI in order to isolate, after agarose gel electrophoresis, the 450 bp NotI-NotI fragment. This fragment was then
5 ligated with the plasmid pVR1012 (Example 1), preferably digested with NotI and dephosphorylated, to give the plasmid pJP058 (5405 bp) (Figure 5). The sequence of the pGM-CSF gene cloned into the plasmid pJP058 was checked and found to be identical to that
10 available in the GenBank database (accession No. D21074).

Example 6: Production of the purified plasmids for the vaccination of pigs

15 *Escherichia coli* K12 bacteria (strains DH10B or SCS1) were transformed with the plasmids pJP109, pJP111, pJP058, pJP120 and pJP121 of Examples 1 to 5 *supra*. The five transformed clones obtained respectively with these five plasmids were then cultured separately, with
20 shaking at +37°C, in Luria-Broth (LB) medium. The bacterial cultures were harvested at the end of the exponential phase and the plasmids were extracted according to the alkaline lysis technique. The extracted plasmids were then purified on a caesium
25 chloride gradient according to the technique described by Sambrook et al. (Molecular Biology: A Laboratory Manual, 2nd Edition, 1989, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY). After final
30 extraction of ethidium bromide and precipitation in the presence of absolute ethanol, the purified plasmids were resuspended in TE buffer (1 mM Tris/EDTA, pH 8.0) in order to obtain stock solutions containing 2 mg of plasmid per ml. These stock solutions are stored at
-20°C before use.

35

Example 7: Control of the expression of ORFs 1 and 2 of the PCV-2 virus

In order to control the products of expression of the PCV-2 ORF2 and PCV-2 ORF1 genes, cloned respectively

into the plasmids pJP109 and pJP111, these plasmids were transfected into CHO-K1 (Chinese Hamster Ovary) cells (ATCC No. CCL-61) with the Lipofectamine Plus® transfection kit (Gibco-BRL, Catalogue# 10964-013), following the manufacturer's recommendations for use. 48 hours after transfection, the transfected cells are washed and fixed with a 95% glacial acetone solution for 3 minutes at room temperature. Five monoclonal antibodies specific for the PCV-2 ORF1 proteins (F199 1D3GA and F210 7G5GD) and ORF2 proteins (F190 4C7CF, F190 2B1BC and F190 3A8BC) were used as first antibodies. An anti-mouse IgG conjugate, labelled with Cy3, was used to reveal the specific labelling. A PCV-2 specific fluorescence was observed with the 3 PCV-2 ORF2 monoclonals in the cells transfected with the plasmid pJP109, but not in those transfected with the plasmid pJP111. In contrast, a PCV-2 specific fluorescence was observed with the two PCV-2 ORF1 monoclonals in the cells transfected with the plasmid pJP111, but not in those transfected with the plasmid pJP109. No fluorescence was detected with the PCV-2 monoclonals in CHO cells transfected with the plasmid pVR1012 alone or in the nontransfected CHO cells. The same expression result was obtained with a polyclonal serum specific for the PCV-2 virus. In this case, a fluorescein-labelled anti-pig IgG conjugate was used to detect the specific fluorescence. No fluorescence was detected with this polyclonal serum in CHO cells transfected with the plasmid pVR1012 alone or in the nontransfected CHO cells.

Example 8: Vaccination of pigs with naked DNA

8.1. One-day-old piglets

Groups of piglets obtained by Caesarean on D0 of the protocol, are placed in an isolating unit. These piglets are vaccinated at the age of 2 days by the

intramuscular route with various vaccinal solutions of plasmid. The vaccinal solutions are prepared by diluting the stock solutions in sterile physiological saline (0.9% NaCl).

5 The piglets are vaccinated:

either with the plasmid pJP109 alone

or with the mixture of the plasmids pJP109 and pJP111

or with the mixture of the plasmids pJP109 and pJP058

or with the mixture of the plasmids pJP109, pJP111 and

10 pJP058

The vaccinal solutions comprise 500 µg of each plasmid.

Volume: The vaccinal solutions are injected by the intramuscular route in a total volume of 2 ml. In practice, given the age of the piglets on vaccination

15 (1-2 days), 1 injection of 1 ml is given on each side of the neck (= 2 × 1 ml).

Two injections of vaccine are carried out at two weeks' interval, that is to say on days D2 and D14 of the protocol.

20 A challenge is made on D21 of the protocol by oronasal administration of a viral suspension of a virulent PCV-2 strain. The piglets are then monitored for 3 weeks for the appearance of specific clinical signs of post-weaning multisystemic wasting syndrome in
25 piglets. The signs which are monitored are:

rectal temperature: daily measurement for the first 14 days, then two measurements during the 3rd week following the challenge.

Weight: weighing of the piglets just before the
30 challenge then once per week during the 3 weeks following the challenge.

Collection of blood samples to test for viremia and antibodies: blood samples taken on D2, D14, D21, D28, D35 and D42.

35 Autopsy: on D42, the surviving pigs are humanely killed and undergo autopsy to search for anatomicopathological lesions and to make histological preparations from the liver, the lymph nodes, the spleen, the kidneys and the thymus to search for lesions in these tissues.

8.2. 5-7-week old piglets

5- to 7-week old piglets, no longer having maternal antibodies specific for the PCV-2 virus are vaccinated

5 by the intramuscular route:

either with the plasmid pJP109 alone,

or with the mixture of the plasmids pJP109 and pJP111

or with the mixture of the plasmids pJP109 and pJP058

10 or with the mixture of the plasmids pJP109, pJP111 and pJP058

the vaccinal doses are the same as those indicated in Example 8.1 (500 µg per plasmid). The vaccinal solutions are injected by the intramuscular route in a volume of 2 ml (a single administration of 2 ml, into 15 the neck muscles).

Two vaccinations are performed at 21 days' interval (D0 and D21). A challenge is made 14 days after the last vaccination (D35) by intramuscular administration of a viral suspension of a virulent PCV-2 strain.

20 The pigs are then monitored for 8 weeks for the occurrence of specific clinical signs of the post-weaning multisystemic wasting syndrome in piglets. The clinical monitoring of the piglets after the challenge is identical to that described in Example 8.1 except 25 that the total duration of observation is this time 8 weeks.

Example 9: Vaccination of pigs with DNA formulated with DMRIE-DOPE

30 It is possible to use, in place of the naked plasmid DNA solutions described in Example 8, solutions of plasmid DNA formulated with DMRIE-DOPE. A DNA solution (containing one or more plasmids according to Example 6) at 1 mg/ml is prepared in 0.9% NaCl. A DMRIE-DOPE 35 solution at 0.75 mM is prepared by taking up a lyophilisate of DMRIE-DOPE in a suitable volume of sterile distilled water.

The formation of the plasmid DNA-cationic lipid complexes is achieved by diluting, in equal parts, the

- DMRIE-DOPE solution at 0.75 mM with the DNA solution at 1 mg/ml in 0.9% NaCl. The DNA solution is introduced gradually, with the aid of a syringe mounted with a 26G needle, along the wall of the vial containing the cationic lipid solution so as to avoid the formation of foam. Gentle shaking is carried out as soon as the two solutions have been mixed. A composition comprising 0.375 mM DMRIE-DOPE and 500 µg/ml of DNA is finally obtained.
- It is desirable for all the solutions used to be at room temperature for all the operations described above. The DNA/DMRIE-DOPE complex formation is performed at room temperature for 30 minutes before immunizing the pigs.
- The pigs are then vaccinated according to the conditions described in Examples 8.1. and 8.2.

Example 10 : Vaccination of piglets and results

1st experiment :

- Groups of 3 or 4 piglets, caesarian-derived day 0 are placed into isolators. The piglets are vaccinated day 2 either with pJP109 alone or with pJP109 and pJP111 plasmids mixture and with a physiological solution for the control group. Each plasmid is diluted in sterile physiological solution (NaCl 0,9%) at 250 µg/µl final concentration. A 2 ml volume is injected by intramuscular route in two points of 1 ml (1 point each side of the neck). A second injection of vaccine or placebo is administered day 14. Vaccination with DNA is well tolerated by piglets and no evidence for adverse reaction to vaccination is noted. The piglets are challenged day 21 by oronasal administration of PCV-2 viral suspension, 1 ml in each nostril. After challenge piglets are weighed once a week. Rectal temperatures are recorded on days 17, 21, 22, 24, 27, 29, 31, 34, 37, 41, 44. Day 44 fecal swabs are collected from each piglet for PCV-2 shedding. The virus is detected and

quantified by quantitative PCR. Day 45 necropsies are performed and tissue samples are collected for virus isolation.

5 • Clinical symptoms :

There is no significant difference for the mean body weight gains or the mean body temperatures between groups.

10 • Necropsy lesions :

The only gross finding noted in pigs at termination is bronchial lymphadenopathy. The lesions are scored according the following criteria.

0 = no visible enlargement of lymph nodes

15 1 = mild lymph nodes enlargement, restricted to bronchial lymph nodes

2 = moderate lymph nodes enlargement, restricted to bronchial lymph nodes

20 3 = severe lymph nodes enlargement, extended to bronchial submandibullar prescapular and inguinal lymph nodes.

std is an abbreviation for standard deviation

N is for number of animals in each group

25	Groups	Lymphadenopathy scores		
		mean	std	N
	pJP109	1.2	1.3	4
	pJP109 + pJP111	2.0	1.7	3
30	controls	3.0	0.0	3

N = number of piglets in each group

A reduction of the lymph node lesions is observed in 3 out 4 piglets immunized with pJP109 and 1 out 3
35 piglets immunized with pJP109 and pJP111 plasmids

mixture. This difference is not significant ($p > 0.05$) due to the high value of the standard deviations (std).

5 • Virus load in lymph nodes tissues:

Quantitative virus re-isolation is performed on tissue homogenates prepared from bronchial and mesenteric lymph nodes.

10 The data presented correspond to the virus titers in tissue homogenates after transformation in \log_{10} .

PCV-2 titers					
Groups	Bronchial LN		Mesenteric LN		
	mean	Std	mean	std	N
PJP109	0.9	0.8	0.9	0.8	4
PJP109 + pJP111	0.7	0.6	0.2	0.2	3
Controls	2.0	1.1	1.8	1.1	4

15 Bronchial lymph nodes seem to contain the most infectious virus. A reduction of the viral load is observed in bronchial and mesenteric lymph nodes from piglets immunized with either pJP109 or pJP109 + pJP111 plasmids mixture. This reduction is significant ($p \leq$
20 0.05 for the plasmids mixture.

• Viral excretion:

25 Post challenge fecal swabs are assessed for shedding PCV-2 by PCR based on amplification of PCV-2 orf2. Each assay is performed in triplicate on 2 ml of sample. Unvaccinated controls are negative for PCV-2 prior challenge and positive after challenge confirming the validity of the PCR assay.

Value are expressed as \log_{10} (number of molecules of PCV-2 DNA in 2 μ l sample).

5	Log₁₀ number of PCV-2 DNA molecules			
	Groups	mean	std	N
	pJP109	3.3	0.3	4
	pJP109 + pJP111	2.9	0.7	3
10	Controls	3.6	0.6	4

The differences between groups are not significant ($p > 0.05$).

15 **2nd experiment :**

14 day-old conventional piglets (8 per group) are immunized with 2 administrations of the pJP109 and pJP111 plasmids mixture formulated with DMRIE DOPE day 0 and day 20. For each administration 2 ml are injected by intramuscular route on the side of the neck behind the ear. The vaccine composition is 250 μ g for each plasmid /ml of physiological solution (0,9% NaCl) and 0.375 mM DMRIE DOPE.

For control group piglets are injected with the physiological solution.

Day 32 the piglets are challenged by oronasal route, introducing 5 ml of PCV-2 viral suspension at a $10^{5.8}$ TCID₅₀/ml titer with a syringe in each nostril.

The piglets are monitored for clinical symptoms, prostration, vomiting, dyspnea, cough, anorexia and hyperthermia (rectal temperature is recorded every day during 28 days post challenge) slower growth (piglets are weighed days 32, 40, 46, 53, 60). The symptoms are

scored according the following criteria: Annex1 (The score for one piglet is equal to the sum of the scores corresponding to the different days of observation)

- 5 Day 60 necropsies are performed and the lesions are scored according the following criteria: Annex2 (The score for one piglet is equal to the sum of the scores corresponding to each organ observed)
- 10 Tissue samples are collected, in particular lymph nodes.

Rectal swabs are collected days 32, 39, 42, 46, 49, 53, 56, 60 to follow viral excretion.

15

- Clinical symptoms:

A significant reduction of the clinical symptoms is observed in the group of immunized piglets compared to controls. In the control group 1 piglet died with PMWS symptoms and none in the vaccinated group.

20

		Clinical scores		
Groups		mean	std	N
25	Vaccinated	13.5	7.1	8
	Controls	29.3	15.6	8

(p < 0.01 Kruskal-Wallis test)

- 30 A significant reduction of the duration of the post challenge hyperthermia is observed in the group of immunized piglet (p ≤ 0.05).

35

Duration (days) of rectal temperature $\geq 40^{\circ}\text{C}$

	Groups	mean	std	N
	Vaccinated	1.9	2.0	8
5	Controls	8.4	3.9	8

The daily weight gain post challenge is not significantly different between vaccinated and control groups.

10 • Necropsy lesions:

A significant reduction of the lesions is observed in the immunized piglets compared to controls in particular for lymphadenopathy ($p \leq 0.05$).

15 **Global lesions and lymphadenopathy scores**

	Groups	mean	std	N
	Global lesions			
	Vaccinated	7.6	3.3	8
	Controls	13.1	7.5	8

20

Lymph node scores

	Vaccinated	3.1	2.7	8
	Controls	5.7	2.9	8

25

• Virus load in lymph nodes tissues:

The virus load in mesenteric and mediastinal lymph nodes is determined by immunochemistry.

30 The following criteria is used for the scores :

- 0 = lack of fluorescence
- 1 = some fluorescent foci on some organ slides
- 2 = approximately 1 foci per shot
- 3 = wholly fluorescent organ.

A significant reduction of the virus load is observed in the immunized groups ($p \leq 0.05$).

5		Virus load				
	Groups	Mesenteric LN		Mediastinal LN N		
		mean	std	mean	std	
	Vaccinated	0.5	0.6	1.3	0.2	8
10	Controls	1.8	0.8	2.0	0.8	8

• Viral excretion

The faecal swabs are assessed by PCR for PCV-2 shedding. The results are scored according the following criteria :

0 = absence of PCV-2

1 = presence of PCV-2

In the immunized group 38% of the piglets versus 88% in the control group excrete PCV-2 in the feces. The duration of viral excretion is significantly reduced in vaccinated group compared to controls.

	Mean duration of viral excretion (days)			
25	Groups	mean	std	N
	Vaccinated	1.2	2.1	8
	Controls	11.4	6.3	8

It should be clearly understood that the invention defined by the appended claims is not limited to the specific embodiments indicated in the description above, but encompasses the variants which depart from neither the scope nor the spirit of the present invention.

ANNEXE 1 : Scores for clinical signs

signs	score
Prostration	0 no, 1 yes ; 2 can't get up
vomiting	0 no, 1 yes
dyspnea	0 no, 1 moderate ; 2 high
cough	0 no, 1 yes
anorexia	0 no, 1 yes
hyperthermia	0 no, 1 $\geq 40^{\circ}\text{C}$; 2 $\geq 41^{\circ}\text{C}$
growing	0 no, 1 DWG week $x \leq$ DWG week $x-1$ and > 100 grams per day
	2 DWG of the week ≤ 100 grams per day
death	0 no, x score of day just before the death
for a day the score is the sum of the score of each sign	

ANNEXE 2 : Scores for macroscopic lesions


skin (color)	normal	0
	white	1
	yellow	2
corpulence	normal	0
	thin	1
	very thin	2
	cachectic	3
mucous	normal	0
	white	1
	yellow	2
sub.cut. Conjonctif	normal	0
	brillant	1
	yellow	2
ganglions (gg)	normal	0
	1 large and or congestive	1
	> 1 large and or congestive	2
	> 1 very large	3
thoracic fluide	normal	0
	brillant	1
	visible	2
heart	normal	0
	lesion	1
lungs	normal	0
	lesion ≤ 4	1
	lesion $> 4 \leq 6$	2
	lesion > 6	3
pleura	normal	0
	lesion	1
ascite	normal	0
	brillant	1
	visible	2
peritoneum	normal	0
	lesion	1
stomach	normal	0
	lesion	1
	ulcer	2
small intestine	normal	0
	lesion	1
large intestine	normal	0
	lesion	1
Peyers plaques	normal	0
	visible on 1 part of the intestine	1
	visible on 2 part of the intestine	2
	very importante	3
liver	normal	0
	lesion	1
kidney	normal	0
	lesion	1
bladder	normal	0
	lesion	1

CLAIMS

1. Immunogenic preparation or vaccine comprising,
 5 on the one hand, a plasmid encoding and expressing a gene selected from the group consisting of ORF1 of PCV-2, ORF2 of PCV-2, ORF1 of PCV-1 and ORF2 of PCV-1, and, on the other hand, an element capable of increasing the immune response directed against the
 10 product of expression of the gene.

2. Immunogenic preparation or vaccine according to Claim 1, characterized in that the element capable of increasing the immune response comprises as adjuvant a cationic lipid of formula

15



in which R₁ is a saturated or unsaturated linear aliphatic radical having from 12 to 18 carbon atoms, R₂ is another aliphatic radical comprising from 2 to 3
 20 carbon atoms, andt X is an hydroxyle ou amine group.

3. Immunogenic preparation or vaccine according to Claim 2, characterized in that the cationic lipid is DMRIE.

4. Immunogenic preparation or vaccine according to
 25 Claim 3, characterized in that the DMRIE is coupled to a neutral lipid.

5. Immunogenic preparation or vaccine according to Claim 4, characterized in that the DMRIE is coupled to DOPE.

30 6. Immunogenic preparation or vaccine according to Claim 1, characterized in that the element capable of increasing the immune response comprises a carbomer as adjuvant.

7. Immunogenic preparation or vaccine according to Claim 1, characterized in that the element capable of increasing the immune response comprises a porcine cytokine.

5 8. Immunogenic preparation or vaccine according to Claim 7, characterized in that the porcine cytokine is GM-CSF.

9. Immunogenic preparation or vaccine according to Claim 7 or 8, characterized in that it comprises a
10 plasmid encoding and expressing the porcine cytokine.

10. Immunogenic preparation or vaccine according to Claim 1, characterized in that the element capable of increasing the immune response comprises a porcine cytokine and a compound selected from the group
15 comprising DMRIE, DMRIE/DOPE and carbomer, as adjuvant.


11. Immunogenic preparation or vaccine according to any one of Claims 1 to 10, characterized in that it comprises a plasmid encoding and expressing another porcine immunogen.

ABSTRACT

DNA vaccine - PCV

5 The invention relates to immunogenic preparations
or vaccines comprising, on the one hand, a plasmid
encoding and expressing a gene from PCV, in particular
selected from the group consisting of ORF1 of PCV-2,
ORF2 of PCV-2, ORF1 of PCV-1 and ORF2 of PCV-1, and, on
10 the other hand, an element capable of increasing the
immune response directed against the product of
expression of the gene, which can be a carbomer, a
porcine cytokine, e.g. GM-CSF or a cationic lipid of
formula

15



in which R₁ is a saturated or unsaturated linear
aliphatic radical having from 12 to 18 carbon atoms, R₂
is another aliphatic radical comprising from 2 to 3
20 carbon atoms, and X is an hydroxyle ou amine group.
The cationic lipid can be DMRIE, possibly coupled with
DOPE.

25

30

Figure 1/5
Plasmid pJP109




Figure 2/5
Plasmid pJP111




Figure 3/5
Plasmid pJP120




Figure 4/5
Plasmid pJP121





Figure 5/5
Plasmid pJP058



DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY
(Includes reference to PCT International Applications)

FROMMER LAWRENCE & HAUG, LLP
File No.: 454313-2335.1

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first and joint inventor (if plural, names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention ENTITLED:

DNA VACCINE - PCV

the specification of which:

- ☐ is attached hereto
☒ was filed with/transmitted to USPTO on MAY 31, 2000 as:
☒ United States Application Serial No. _____
☐ as the National Phase or Continuation or Continuation-in-Part of PCT
Application No. _____, filed _____,
designating the U.S., and published as _____ on _____,
☒ with amendments through DATE EVEN HEREWITH (if applicable, give details).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code § 119 (a) - (d) or § 365 (b) of any foreign application(s) for patent or inventor's certificate, or § 365 (a) of any PCT International application(s) designating at least one country other than the United State of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT International applications designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) on which priority is claimed:

Prior Foreign/PCT Application(s) [list additional applications on separate page]:

<u>Country (or PCT)</u>	<u>Application Number:</u>	<u>Filed (Day/Month/Year)</u>	Priority Claimed:	
			<u>Yes</u>	<u>No</u>

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional

application(s) listed below.

60/138,352
(Application Number)

JUNE 10, 1999
(Filing Date)

I hereby claim the benefit under Title 35, United States Code § 120 of any United States application(s) or § 365 (c) of any PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior United States or PCT International application(s) in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Prior U.S. (or U.S.-designating PCT) Application(s) [list additional applications on separate page]:
U.S. Serial No.: Filed (Day/Month/Year) PCT Application No. Status (patented, pending, abandoned)

I hereby appoint Thomas J. Kowalski, Registration No. 32,147, and FROMMER LAWRENCE & HAUG, LLP or their duly appointed associates, my attorneys or agents, with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to file continuation and divisional applications thereof, to receive the Patent, and to transact all business in the Patent and Trademark Office and in the Courts in connection therewith, and to insert the Serial Number of the application in the space provided above, and specify that all communications about the application are to be directed to the following correspondence address:

Thomas J. Kowalski, Esq.
c/o FROMMER LAWRENCE &
HAUG LLP
745 Fifth Avenue
New York, NY 10151
FAX (212) 588-0500

Direct all telephone calls to: (212) 588-0800
to the attention of:
Thomas J. Kowalski

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

INVENTOR(S):

Signature: _____ Date: _____

Full name of first inventor: Francis Jean-Christophe, AUDONNET
Residence: 119 rue de Créqui, 69006 Lyon, France
Citizenship: French

Signature: _____ Date: _____

Full name of second inventor: Michel BUBLOT
Residence: 126 Dumbarton Drive, Delmar, New York 12054
Citizenship: French

Signature: _____ Date: _____

Full name of third inventor: Jennifer Maria PEREZ
Residence: 27 Smith Hill Road, East Nassau, New York 12062
Citizenship: U.S.

Signature: _____ Date: _____

Full name of fourth inventor: Catherine Elisabeth CHARREYRE
Residence: 42 Rue Ferdinand Gauthier, 69720 Saint-Laurent De Mure, France
Citizenship: French

Post Office Address(es) of inventors [if different from residence]:

NOTE: In order to qualify for reduced fees available to Small Entities, each inventor and any other individual or entity having rights to the invention must also sign an appropriate separate "Verified Statement (Declaration) Claiming [or Supporting a Claim by Another for] Small Entity Status" form [e.g. for Independent Inventor, Small Business Concern, Nonprofit Organization, Individual Non-Inventor].

SEQUENCE LISTING

<110> AUDONNET, Jean-Christophe Francis
BUBLOT, Michel Joseph Marie
PEREZ, Jennifer Maria
CHARREYRE, Catherine ELISABETH

<120> DNA vaccine - PCV

<130> DNA vaccine PCV

<140> US 60/138,352

<141> 1999-06-10

<160> 10

<170> PatentIn Ver. 2.1

<210> 1

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide

<400> 1

catcatcatg tcgacatgac gstatccaagg aggcg

35

<210> 2

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide

<400> 2

tactactaca gatcttttagg gtttaagtgg ggggtc

36

<210> 3

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide

<400> 3

catcatcatg tcgacatgcc cagcaagaag aatgg

35

<210> 4

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide

<400> 4

tactactaca gatcttcagt aattttatttc atatgg

36

<210> 5

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide

<400> 5

catcatcatg tcgacatgac gtggccaagg aggcg

35

<210> 6

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide

<400> 6

tactactaca gatctttatt tatttagagg gtcttttagg

40

<210> 7
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
oligonucleotide

<400> 7
catcatcatg tcgacatgcc aagcaagaaa agcgg 35

<210> 8
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
oligonucleotide

<400> 8
tactactaca gatcttcagt aattttatattt atatgg 36

<210> 9
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
oligonucleotide

<400> 9
tatgcggcog ccacccatgtg gctgcagaac ctg 33

<210> 10
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
oligonucleotide

<400> 10

tatgcggccg ctacgtatca cttctgggct gggt

34